1. Introduction
1.1 Ageing - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Ageing
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Ageing - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs-Phase II
5.1.1 Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
5.1.2 Longeveron Mesenchymal Stem Cells (LMSCs)
5.1.3 Rapamycin
5.2 Clinical Stage Drugs-Phase I
5.2.1 GLPG1205
5.2.2 RCS-01
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 AgelessRx
9.2 Galapagos NV
9.3 Longeveron Inc.
9.4 RepliCel Life Sciences, Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix